Skip to main content
Equibles
TGTX logo

TGTX · Tg Therapeutics, Inc.

Track TGTX — free

Use TGTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TGTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$53.89 -1.50 (-2.71%) At close · Sep 11
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$8.25B
Shares
153.07M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$53.89 Open$55.71 Day$53.47–56.26 52W close$26.94–59.06 Avg vol 30d2.1M Short int30.1M · 19.7% float · 15.9d Short vol58% Last earningsAug 3, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 1, 2026 Est · unconfirmed · in 7 wks
Latest filing: 10-Q
filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$799.54M
Trailing 12 months
Net income (TTM)
$441.49M
Trailing 12 months
Revenue growth YoY
+70.3%
Year over year
Operating margin
17.1%
Trailing 12 months
P / E (TTM)
19.7
Trailing earnings · reciprocal yield 5.1%
FCF yield
0.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-3.2%
Year over year · fewer shares
Price change (1Y)
+66.0%
Trailing year
Short interest
19.7%
Latest settlement · 15.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +36%
above
Price vs 50-day avg +1%
above
RSI (14) 50
neutral
MACD trend Negative
52-week position 84%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +12%
trailing
6-month return +79%
trailing
YTD return +81%
this year
Relative strength +61%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $54 › 200d $39 — 50d above 200d
Institutional flow Accumulating
+17% holders QoQ · +107 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
19.68% of float · ▲ +0.1% MoM · 15.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
433 holders — near 3-yr high, broad support
Squeeze score 77
high risk · 0–100
Fundamentals
Fair
Revenue growth −58%
Y/Y
EPS growth +1747%
Y/Y
Free cash flow $-25.0M
Valuation P/E 19.7
in line
Buyback $400.0M
authorized
Balance sheet $7.5M
net debt
Quant / Vol
risk profile
Very High
Volatility 46%
annualized · 1-yr
Max drawdown −27%
past year
ATR 4.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Jun 30, 2026
fourth quarter 2026
Quarterly U.S. net revenue at least $250M
full year 2026
Total global revenue Initiated $950M
prior FY $616.29M midpoint +54.1% Y/Y
Full year OPEX excluding stock-based compensation Non-GAAP Initiated $350M – $400M
full year
OPEX, excluding stock-based compensation $350M – $400M
Prior guidance period ended · from the 8-K filed Aug 6, 2024
U.S. BRIUMVI net product revenue · full year 2024 $290M – $300M
Guided vs delivered · last 1 settled
Net revenues full year 2022
guided $50M – $75M
$2.79M Miss −95.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+36% Bullish
Price vs 50-day avg
+1% Bullish
RSI (14)
50 Neutral
MACD trend
Negative Bearish
52-week position
84% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $54 › 200d $39 — 50d above 200d
Institutional flow Accumulating
+17% holders QoQ · +107 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
19.68% of float · ▲ +0.1% MoM · 15.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
433 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $27 Now $54 · 84% Range high $59
vs 200-day avg +36% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TGTX
Tg Therapeutics, Inc.
this stock
$8.25B +80.8% -58.4% 19.7 19.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
433
% held
75.2%
Net QoQ
+5.5M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
322
View
Short & Settlement
Short Interest Rising
Shares short
30.1M
Days to cover
15.9d
Change
+19.2K sh
View
Short Volume
Short vol %
58%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
3.7K
Value
$182.4K
As of
Aug 13, 2026
View
Off-Exchange
Off-exchange %
35.0%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Christopher L. Jacobs
Amount
$1.0K–$15.0K
Traded
Sep 8, 2020
View
Financials
Financials
Revenue (FY)
$616.3M
Net income (FY)
$447.2M
EPS diluted
$2.77
View
Buybacks
Authorized · 2 programs
$400.0M
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 5, 2026
This year
14
View
Proposed Sales
Value
$274.8K
Shares
5.0K
Filed
Sep 10, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 3, 2026
View

Performance

5D 20D 120D MTD YTD
TGTX -5.0% +12.4% +79.2% -0.8% +80.8%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -3.8% +14.2% +61.4% -0.4% +68.7%

Capital returns

Buyback programs · 2 active · as of Jun 30, 2026
Authorized (total)
$400.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1001316 CUSIP 88322Q108 13F (30d) 101 filings 100 filers Visit website Investor relations